Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis.

PubWeight™: 1.77‹?› | Rank: Top 3%

🔗 View Article (PMID 20157022)

Published in Arch Dermatol on February 01, 2010

Authors

Lidian L A Lecluse1, Rieke J B Driessen, Phyllis I Spuls, Elke M G J de Jong, Steven O Stapel, Martijn B A van Doorn, Jan D Bos, Gert-Jan Wolbink

Author Affiliations

1: Department of Dermatology, Academic Medical Center, University of Amsterdam, Room A0-252, PO Box 22700, 1100 DE Amsterdam, the Netherlands. l.l.lecluse@amc.uva.nl

Articles citing this

Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov (2010) 4.47

Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J (2012) 1.58

Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol (2012) 1.21

Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol (2015) 1.00

The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther (2010) 0.98

The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford) (2013) 0.90

Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy. PLoS One (2012) 0.89

The utility of modeling and simulation approaches to evaluate immunogenicity effect on the therapeutic protein pharmacokinetics. AAPS J (2012) 0.86

A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis. Int J Rheum Dis (2015) 0.86

Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity. MAbs (2015) 0.84

Stratification of antibody-positive subjects by antibody level reveals an impact of immunogenicity on pharmacokinetics. AAPS J (2012) 0.79

Practical application of acid dissociation in monitoring patients treated with adalimumab. Rheumatol Int (2014) 0.76

Weight-Based Adaptation of TNF-Antagonist Induction versus Maintenance Dose. Case Rep Dermatol (2011) 0.75

Anti-TNFα therapy in the management of psoriasis: experience of a state referral center. An Bras Dermatol (2014) 0.75

Strategies for treatment with anti-tumor necrosis factor agents in psoriasis: maintaining efficacy and safety for the long haul. Arch Dermatol (2010) 0.75

The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab. PLoS One (2015) 0.75

Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies. Br J Clin Pharmacol (2017) 0.75

Articles by these authors

In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol (2006) 2.44

Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med (2003) 2.12

Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc (2004) 1.95

How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol (2009) 1.87

Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther (2005) 1.85

The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol (2002) 1.84

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis (2010) 1.81

Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One (2010) 1.73

Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol (2011) 1.71

Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients. J Invest Dermatol (2006) 1.62

Current and future treatment options for acne. J Dermatolog Treat (2006) 1.60

Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol (2009) 1.56

Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition. J Immunol (2007) 1.55

Formation of fibrosis after nonablative and ablative fractional laser therapy. Dermatol Surg (2011) 1.41

UVB 311 nm tolerance of vitiligo skin increases with skin photo type. Acta Derm Venereol (2005) 1.40

Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis (2007) 1.37

Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum (2002) 1.22

Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics (2002) 1.22

Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. Eur J Cell Biol (2002) 1.14

Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis. Arthritis Rheum (2013) 1.12

Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther (2004) 1.09

The burden of vitiligo: patient characteristics associated with quality of life. J Am Acad Dermatol (2009) 1.07

Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin. PLoS One (2009) 1.06

Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges (2011) 1.04

Overview of psoriasis. Dermatol Ther (2004) 1.04

Skin barrier function in healthy subjects and patients with atopic dermatitis in relation to filaggrin loss-of-function mutations. J Invest Dermatol (2010) 1.04

Scleredema diabeticorum case series: successful treatment with UV-A1. Arch Dermatol (2008) 1.01

Benzoyl peroxide/clindamycin/UVA is more effective than fluticasone/UVA in progressive macular hypomelanosis: a randomized study. J Am Acad Dermatol (2006) 0.97

Interventions for nail psoriasis. Cochrane Database Syst Rev (2013) 0.97

Langerhans cells favor skin flora tolerance through limited presentation of bacterial antigens and induction of regulatory T cells. J Invest Dermatol (2013) 0.95

Off-label use of azathioprine in dermatology: a systematic review. Arch Dermatol (2011) 0.94

T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. Clin Cancer Res (2011) 0.92

Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. J Am Acad Dermatol (2009) 0.92

IgE to Bet v 1 and profilin: cross-reactivity patterns and clinical relevance. J Allergy Clin Immunol (2002) 0.92

Health-related quality of life in patients with cutaneous rosacea: a systematic review. Acta Derm Venereol (2015) 0.92

Digital image analysis for the evaluation of the inflammatory infiltrate in psoriasis. Arch Dermatol Res (2005) 0.91

Physical burden of symptoms in patients with localized scleroderma and eosinophilic fasciitis. Arch Dermatol (2008) 0.91

Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. Liver Int (2007) 0.91

Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled pilot study. J Am Acad Dermatol (2011) 0.90

Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis. Dermatology (2002) 0.90

Biomarkers for methotrexate-induced liver injury: urinary protein profiling of psoriasis patients. Toxicol Lett (2013) 0.90

Increased frequencies of IL-31-producing T cells are found in chronic atopic dermatitis skin. Exp Dermatol (2012) 0.89

Laboratory tests and identified diagnoses in patients with physical and chronic urticaria and angioedema: A systematic review. J Am Acad Dermatol (2003) 0.89

Detection of soluble human granzyme K in vitro and in vivo. Eur J Immunol (2005) 0.89

The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc (2004) 0.89

T cells in psoriatic lesional skin that survive conventional therapy with NB-UVB radiation display reduced IFN-gamma expression. Arch Dermatol Res (2004) 0.89

Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis. Arch Dermatol Res (2004) 0.88

What patients think about E-health: patients' perspective on internet-based cognitive behavioral treatment for patients with rheumatoid arthritis and psoriasis. Clin Rheumatol (2013) 0.88

Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. PLoS One (2010) 0.88

Psychological distress in patients with morphea and eosinophilic fasciitis. Arch Dermatol (2009) 0.88

Biopsychosocial mechanisms of chronic itch in patients with skin diseases: a review. Acta Derm Venereol (2008) 0.88

Etanercept: an overview of dermatologic adverse events. Arch Dermatol (2011) 0.87

Deposition of nucleosomal antigens (histones and DNA) in the epidermal basement membrane in human lupus nephritis. Arthritis Rheum (2003) 0.87

Clinical differences between atopic and atopiform dermatitis. J Am Acad Dermatol (2008) 0.87

The course of life of patients with childhood atopic dermatitis. Pediatr Dermatol (2009) 0.86

Validation and refinement of the Millennium Criteria for atopic dermatitis. J Dermatol (2011) 0.86

Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine. Arch Dermatol (2004) 0.86

Ultraviolet A phototherapy for sclerotic skin diseases: a systematic review. J Am Acad Dermatol (2008) 0.86

Expression of terminal complement components by human keratinocytes. Mol Immunol (2007) 0.85

Effectiveness of a multidisciplinary itch-coping training programme in adults with atopic dermatitis. Acta Derm Venereol (2009) 0.85

A rapid assay for on-site monitoring of infliximab trough levels: a feasibility study. Anal Bioanal Chem (2013) 0.84

Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study. Am J Clin Dermatol (2009) 0.84

Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin. J Am Acad Dermatol (2004) 0.83

Human keratinocytes produce the complement inhibitor factor I: Synthesis is regulated by interferon-gamma. Mol Immunol (2007) 0.83

High prevalence of autoimmune thyroiditis in children and adolescents with vitiligo. Horm Res Paediatr (2013) 0.83

Ultraviolet B radiation induces a transient appearance of IL-4+ neutrophils, which support the development of Th2 responses. J Immunol (2002) 0.83

Non-ablative 1,550 nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled split-face study. Lasers Surg Med (2010) 0.82

Wet work and hand eczema in apprentice nurses; part I of a prospective cohort study. Contact Dermatitis (2013) 0.82

Non-ablative 1550 nm fractional laser therapy not effective for erythema dyschromicum perstans and postinflammatory hyperpigmentation: a pilot study. J Dermatolog Treat (2011) 0.82

Topical treatments in psoriasis: today and tomorrow. Clin Dermatol (2008) 0.82

Proceedings of the 4th Georg Rajka International Symposium on Atopic Dermatitis, Arcachon, France, September 15-17, 2005. J Allergy Clin Immunol (2006) 0.82

Aberrant function of peripheral blood myeloid and plasmacytoid dendritic cells in atopic dermatitis patients. J Allergy Clin Immunol (2008) 0.82

Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor. Arch Dermatol Res (2007) 0.82

Postelicitation model of allergic contact dermatitis for predicting the efficacy of topical drugs. Exp Dermatol (2008) 0.82

Neutrophils infiltrating ultraviolet B-irradiated normal human skin display high IL-10 expression. Arch Dermatol Res (2004) 0.82

Human keratinocytes produce the complement inhibitor factor H: synthesis is regulated by interferon-gamma. Mol Immunol (2005) 0.81

Ultraviolet-B irradiation decreases IFN-gamma and increases IL-4 expression in psoriatic lesional skin in situ and in cultured dermal T cells derived from these lesions. Exp Dermatol (2003) 0.81

Accuracy and reliability of teledermatoscopy with images taken by general practitioners during everyday practice. J Telemed Telecare (2013) 0.81

Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin Immunol (2002) 0.80

Tertiary teledermatology: a systematic review. Telemed J E Health (2010) 0.80

Acitretin treatment in (pre)malignant skin disorders of renal transplant recipients: Histologic and immunohistochemical effects. J Am Acad Dermatol (2004) 0.80

In situ demonstration of CD40- and CD154-positive cells in psoriatic lesions and keratinocyte production of chemokines by CD40 ligation in vitro. J Pathol (2004) 0.80

The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis. Br J Clin Pharmacol (2013) 0.79

Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists. Br J Clin Pharmacol (2011) 0.79

INK4-ARF and p53 mutations in metastatic cutaneous squamous cell carcinoma: case report and archival study on the use of Ink4a-ARF and p53 mutation analysis in identification of the corresponding primary tumor. Am J Surg Pathol (2005) 0.79

Ablative fractional laser therapy as treatment for Becker nevus: a randomized controlled pilot study. J Am Acad Dermatol (2011) 0.79

Progressive macular hypomelanosis is associated with a putative Propionibacterium species. J Invest Dermatol (2009) 0.79

Expression of IL-20 in synovium and lesional skin of patients with psoriatic arthritis: differential response to alefacept treatment. Arthritis Res Ther (2012) 0.79

Familial multiple discoid fibromas: a look-alike of Birt-Hogg-Dubé syndrome not linked to the FLCN locus. J Am Acad Dermatol (2011) 0.79

Suppression of different phases of systemic contact hypersensitivity by urocanic acid oxidation products. Photochem Photobiol (2004) 0.79